Current guidelines for cervical cancer screening

Author： Schwaiger Constance Aruda Mary LaCoursiere Sheryl Rubin Richard

ISSN： 1041-2972

Source： Journal of the American Academy of Nurse Practitioners, Vol.24, Iss.7, 2012-07, pp. : 417-424

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

AbstractPurpose: To provide evidence-based information that will guide nurse practitioners in instituting the most current cervical cancer screening recommendations.Data sources: A literature search covering the years 2006 to the present conducted through Medline, CINAHL, and OVID.Conclusions: Human papillomavirus (HPV) cervical infections are highly prevalent among females under 21 years, yet this age group has a low incidence of cervical cancer. For young women, 90% of HPV infections regress in 24 months, and, in longitudinal studies, no invasive cervical cancer was detected. HPV co-testing is effective for women age 30 and over.Implications for practice: Current scientific evidence supports initiating cervical cancer screening for immunocompetent women at age 21, biennial screening between ages 21 and 29, and HPV DNA co-testing for women over 30. Nurse practitioners play an important role in integrating the newest guidelines into practice and improving the quality of healthcare regarding women's cervical health and cancer prevention.